A Phase IV, Non-Randomized, Open-Label Trial Evaluating The Safety Of 625 mg Formulation Of VIRACEPT When Administered To HIV-Infected Women During Pregnancy.
Phase of Trial: Phase IV
Latest Information Update: 27 Apr 2011
At a glance
- Drugs Nelfinavir (Primary)
- Indications HIV infections; Pregnancy
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 14 Apr 2009 Actual initiation date changed from Feb 2006 to Mar 2006 as reported by ClinicalTrials.gov.
- 13 May 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov